Longeveron (LGVN) Competitors $1.65 +0.05 (+3.13%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LGVN vs. MNOV, DERM, SKYE, IMUX, ANRO, CNTX, AVTX, PYXS, IPSC, and ORMPShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include MediciNova (MNOV), Journey Medical (DERM), Skye Bioscience (SKYE), Immunic (IMUX), Alto Neuroscience (ANRO), Context Therapeutics (CNTX), Avalo Therapeutics (AVTX), Pyxis Oncology (PYXS), Century Therapeutics (IPSC), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. MediciNova Journey Medical Skye Bioscience Immunic Alto Neuroscience Context Therapeutics Avalo Therapeutics Pyxis Oncology Century Therapeutics Oramed Pharmaceuticals Longeveron (NASDAQ:LGVN) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the media refer more to LGVN or MNOV? In the previous week, MediciNova had 1 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for Longeveron. Longeveron's average media sentiment score of 0.99 beat MediciNova's score of 0.37 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in LGVN or MNOV? MediciNova received 194 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.12% of users gave Longeveron an outperform vote while only 48.84% of users gave MediciNova an outperform vote. CompanyUnderperformOutperformLongeveronOutperform Votes1694.12% Underperform Votes15.88%MediciNovaOutperform Votes21048.84% Underperform Votes22051.16% Which has better earnings and valuation, LGVN or MNOV? MediciNova has lower revenue, but higher earnings than Longeveron. MediciNova is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$1.89M12.93-$21.41M-$6.28-0.26MediciNova$1M106.44-$8.56M-$0.21-10.33 Which has more risk & volatility, LGVN or MNOV? Longeveron has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Do insiders & institutionals believe in LGVN or MNOV? 10.0% of Longeveron shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 19.1% of Longeveron shares are held by insiders. Comparatively, 14.9% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is LGVN or MNOV more profitable? MediciNova has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. MediciNova's return on equity of -17.55% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-967.49% -142.43% -100.84% MediciNova N/A -17.55%-16.62% Do analysts prefer LGVN or MNOV? Longeveron currently has a consensus price target of $8.67, indicating a potential upside of 425.25%. MediciNova has a consensus price target of $9.00, indicating a potential upside of 314.75%. Given Longeveron's stronger consensus rating and higher probable upside, equities research analysts clearly believe Longeveron is more favorable than MediciNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLongeveron beats MediciNova on 10 of the 19 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.48M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.2610.5991.3417.19Price / Sales12.93195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.625.104.794.78Net Income-$21.41M$151.51M$120.07M$225.60M7 Day Performance-11.29%-2.15%-1.89%-1.24%1 Month Performance-11.76%-3.14%11.45%3.36%1 Year Performance-86.80%11.50%30.61%16.58% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron3.4375 of 5 stars$1.65+3.1%$8.67+425.3%-89.8%$24.48M$1.89M-0.2623MNOVMediciNova2.1642 of 5 stars$2.12+1.0%$9.00+324.5%+43.7%$103.98M$1M-9.9510Analyst ForecastPositive NewsDERMJourney Medical2.548 of 5 stars$4.95-2.8%$9.38+89.4%N/A$103.41M$79.18M-5.3690SKYESkye Bioscience2.1878 of 5 stars$3.38+0.9%$18.67+452.3%-10.6%$102.54MN/A0.0011News CoveragePositive NewsGap DownIMUXImmunic2.933 of 5 stars$1.14+0.4%$11.80+939.6%-20.6%$102.24MN/A-0.9270Positive NewsANROAlto Neuroscience3.2563 of 5 stars$3.76-1.8%$20.00+431.9%N/A$101.41M$210,000.000.00N/AGap UpCNTXContext Therapeutics2.9747 of 5 stars$1.35-2.9%$6.80+403.7%+1.0%$101.25MN/A-1.477Positive NewsGap DownAVTXAvalo Therapeutics3.712 of 5 stars$9.65+4.6%N/A-13.7%$100.30M$820,000.000.0040Analyst ForecastNews CoveragePYXSPyxis Oncology2.1442 of 5 stars$1.68+3.4%$10.00+497.0%-2.9%$99.61MN/A-1.5760Analyst ForecastNews CoveragePositive NewsIPSCCentury Therapeutics1.8206 of 5 stars$1.17-4.5%$11.60+895.7%-52.6%$99.06M$2.68M-0.66170High Trading VolumeORMPOramed Pharmaceuticals1.6807 of 5 stars$2.41-2.4%N/A+8.2%$97.15M$1.34M22.4510Analyst UpgradePositive News Related Companies and Tools Related Companies MNOV Alternatives DERM Alternatives SKYE Alternatives IMUX Alternatives ANRO Alternatives CNTX Alternatives AVTX Alternatives PYXS Alternatives IPSC Alternatives ORMP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LGVN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
